Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant intravitreal ranibizumab in high-risk ocular melanoma
ISRCTN35236442Phase 2Terminated
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
- Start
- Apr 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in intraocular melanoma and eye melanoma, sponsored by Liverpool University Hospitals NHS Foundation Trust. Primary endpoint: Response rate. Started Apr 2012; status: terminated.
02
Drugs
ranibizumab
03
Conditions
intraocular melanomaeye melanoma
Beyond the preview
Go deeper on ISRCTN35236442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN35236442.